T-1032

**T-1032** is a selective phosphodiesterase type 5 inhibitor (PDE5 inhibitor) developed as a small molecule drug. Its mechanism of action is the inhibition of phosphodiesterase type 5A (PDE5A), resulting in increased levels of cGMP and potentiation of the NO/cGMP signaling pathway. This mechanism is similar to clinically used PDE5 inhibitors such as sildenafil. Preclinical studies demonstrated that T-1032 induces relaxation of smooth muscle in rat aorta and rabbit corpus cavernosum, and has vasodilator properties, including effects on mean arterial and circulatory filling pressure. T-1032 was investigated for potential therapeutic use in cardiovascular diseases (like angina, heart failure, hypertension), nervous system diseases, and urogenital diseases (like erectile dysfunction). Its development originated with Mitsubishi Tanabe Pharma[1][3][5].

Other names

methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate